High-Throughput Screening Assay for Convalescent Sera in COVID-19: Efficacy, Donor Selection, and Variant...

Area of Science:

• Virology
• Immunology
• Drug Discovery

Background:

• Convalescent sera provide passive immunity via pathogen-specific antibodies.
• Screening assays are vital for evaluating therapeutic efficacy and donor selection.
• Standardized assays are needed for reliable results in COVID-19 serum therapy.

Purpose of the Study:

• To develop a high-content image-based assay for screening convalescent sera against SARS-CoV-2 variants.
• To assess the neutralizing antibody efficacy and specificity of convalescent sera.
• To explore potential synergies between convalescent sera and antiviral agents like NHC.

Main Methods:

• Utilized various cell lines for optimal candidate identification.
• Employed immunofluorescence microscopy to visualize infected cells and antibody effects.
• Performed dose-response analysis to quantify neutralizing activity against SARS-CoV-2 variants.

Main Results:

• Identified convalescent sera with significant neutralizing activity against SARS-CoV-2 variants.
• Demonstrated variable but broad neutralization capabilities in some sera.
• Observed potential synergy between neutralizing antibodies and β-d-N4-hydroxycytidine (NHC).

Conclusions:

• The developed assay effectively screens convalescent sera for therapeutic potential against SARS-CoV-2.
• Findings enhance understanding of neutralizing antibody activity and support COVID-19 serum therapy optimization.
• The study highlights the importance of assessing antibody breadth and potential drug interactions.